Sphingosine-1-phosphate in chronic intestinal inflammation and cancer

Advances in Biological Regulation

Volumn 54, Issue 1, 2014, Pages 112-120

  Nagahashi, Masayuki ^a,b   Hait, Nitai C ^a   Maceyka, Michael ^a   Avni, Dorit ^a   Takabe, Kazuaki ^a,b   Milstien, Sheldon ^a   Spiegel, Sarah ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1-PHOSPHATE;

ANIMAL; CHRONIC DISEASE; ENTEROPATHY; GENETICS; HUMAN; IMMUNOLOGY; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CHRONIC DISEASE; HUMANS; INTESTINAL DISEASES; LYSOPHOSPHOLIPIDS; NEOPLASMS; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84893359343     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2013.10.001     Document Type: Review

References (60)

1. Allende M.L., Dreier J.L., Mandala S., Proia R.L. Expression of the sphingosine-1-phosphate receptor, S1P1, on T-cells controls thymic emigration. JBiol Chem 2004, 279:15396-15401.
2. Alvarez S.E., Harikumar K.B., Hait N.C., Allegood J., Strub G.M., Kim E.Y., et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 2010, 465:1084-1088.
3. Alvarez S.E., Milstien S., Spiegel S. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab 2007, 18:300-307.
4. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
5. Billich A., Bornancin F., Devay P., Mechtcheriakova D., Urtz N., Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. JBiol Chem 2003, 278:47408-47415.
6. Billich A., Bornancin F., Mechtcheriakova D., Natt F., Huesken D., Baumruker T. Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: function in cell survival and IL-1beta and TNF-alpha induced production of inflammatory mediators. Cell Signal 2005, 17:1203-1217.
7. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
8. Brinkmann V., Billich A., Baumruker T., Heining P., Schmouder R., Francis G., et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010, 9:883-897.
9. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., et al. The immune modulator, FTY720, targets sphingosine 1-phosphate receptors. JBiol Chem 2002, 277:21453-21457.
10. Chiba K., Yanagawa Y., Masubuchi Y., Kataoka H., Kawaguchi T., Ohtsuki M., et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. JImmunol 1998, 160:5037-5044.
11. Cyster J.G., Schwab S.R. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 2012, 30:69-94.
12. Daniel C., Sartory N., Zahn N., Geisslinger G., Radeke H.H., Stein J.M. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. JImmunol 2007, 178:2458-2468.
13. De Palma C., Meacci E., Perrotta C., Bruni P., Clementi E. Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium. Arterioscler Thromb Vasc Biol 2006, 26:99-105.
14. Deguchi Y., Andoh A., Yagi Y., Bamba S., Inatomi O., Tsujikawa T., et al. The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice. Oncol Rep 2006, 16:699-703.
15. Fujii T., Tomita T., Kanai T., Nemoto Y., Totsuka T., Sakamoto N., et al. FTY720 suppresses the development of colitis in lymphoid-null mice by modulating the trafficking of colitogenic CD4+ T cells in bone marrow. Eur J Immunol 2008, 38:3290-3303.
16. Fyrst H., Saba J.D. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 2010, 6:489-497.
17. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
18. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
19. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
20. Hait N.C., Allegood J., Maceyka M., Strub G.M., Harikumar K.B., Singh S.K., et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009, 325:1254-1257.
21. Hisano Y., Kobayashi N., Kawahara A., Yamaguchi A., Nishi T. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720. JBiol Chem 2011, 286:1758-1766.
22. Karin M., Lawrence T., Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006, 124:823-835.
23. Kawahara A., Nishi T., Hisano Y., Fukui H., Yamaguchi A., Mochizuki N. The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors. Science 2009, 323:524-527.
24. Kawamori T., Kaneshiro T., Okumura M., Maalouf S., Uflacker A., Bielawski J., et al. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J 2008, 23:405-414.
25. Kawamori T., Osta W., Johnson K.R., Pettus B.J., Bielawski J., Tanaka T., et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 2006, 20:386-388.
26. Kharel Y., Lee S., Snyder A.H., Sheasley-O'neill S.L., Morris M.A., Setiady Y., et al. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. JBiol Chem 2005, 280:36865-36872.
27. Kohno M., Momoi M., Oo M.L., Paik J.H., Lee Y.M., Venkataraman K., et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol 2006, 26:7211-7223.
28. Lee H., Deng J., Kujawski M., Yang C., Liu Y., Herrmann A., et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 2010, 16:1421-1428.
29. Li Y., de Haar C., Chen M., Deuring J., Gerrits M.M., Smits R., et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 2010, 59:227-235.
30. Liang J., Nagahashi M., Kim E.Y., Harikumar K.B., Yamada A., Huang W.-C., et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 2013, 23:107-120.
31. Maceyka M., Harikumar K.B., Milstien S., Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012, 22:50-60.
32. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002, 296:346-349.
33. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
34. Mitra P., Oskeritzian C.A., Payne S.G., Beaven M.A., Milstien S., Spiegel S. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci USA 2006, 103:16394-16399.
35. Nagahashi M., Ramachandran S., Kim E.Y., Allegood J.C., Rashid O.M., Milstien S., et al. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by tumor-induced angiogenesis and lymphangiogenesis. Cancer Res 2012, 72:726-735.
36. Nagahashi M., Ramachandran S., Rashid O.M., Takabe K. Lymphangiogenesis: a new player in cancer progression. World J Gastroenterol 2010, 16:4003-4012.
37. Olivera A., Spiegel S. Sphingosine-1-phosphate as a second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature 1993, 365:557-560.
38. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87:803-809.
39. Paugh S.W., Payne S.G., Barbour S.E., Milstien S., Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 2003, 554:189-193.
40. Pettus B.J., Bielawski J., Porcelli A.M., Reames D.L., Johnson K.R., Morrow J., et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J 2003, 17:1411-1421.
41. Pitson S.M., Moretti P.A., Zebol J.R., Lynn H.E., Xia P., Vadas M.A., et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J 2003, 22:5491-5500.
42. Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. JClin Invest 2008, 118:560-570.
43. Pyne N.J., Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010, 10:489-503.
44. Saleh M., Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 2011, 11:9-20.
45. Sanada Y., Mizushima T., Kai Y., Nishimura J., Hagiya H., Kurata H., et al. Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis. PLoS One 2011, 6:e23933.
46. Sato K., Malchinkhuu E., Horiuchi Y., Mogi C., Tomura H., Tosaka M., et al. Critical role of ABCA1 transporter in sphingosine 1-phosphate release from astrocytes. JNeurochem 2007, 103:2610-2619.
47. Scherer E.Q., Yang J., Canis M., Reimann K., Ivanov K., Diehl C.D., et al. Tumor necrosis factor-alpha enhances microvascular tone and reduces blood flow in the cochlea via enhanced sphingosine-1-phosphate signaling. Stroke 2010, 41:2618-2624.
48. Sensken S.C., Bode C., Graler M.H. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy. JPharmacol Exp Ther 2009, 328:963-969.
49. Snider A.J., Kawamori T., Bradshaw S.G., Orr K.A., Gilkeson G.S., Hannun Y.A., et al. Arole for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J 2009, 23:143-152.
50. Song J., Matsuda C., Kai Y., Nishida T., Nakajima K., Mizushima T., et al. Anovel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. JPharmacol Exp Ther 2008, 324:276-283.
51. Spiegel S., Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 2011, 11:403-415.
52. Strub G.M., Paillard M., Liang J., Gomez L., Allegood J.C., Hait N.C., et al. Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. FASEB J 2011, 25:600-612.
53. Takabe K., Kim R.H., Allegood J.C., Mitra P., Ramachandran S., Nagahashi M., et al. Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. JBiol Chem 2010, 285:10477-10486.
54. Takabe K., Paugh S.W., Milstien S., Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008, 60:181-195.
55. Ullman T.A., Itzkowitz S.H. Intestinal inflammation and cancer. Gastroenterology 2011, 140:1807-1816.
56. Xia P., Wang L., Moretti P.A., Albanese N., Chai F., Pitson S.M., et al. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. JBiol Chem 2002, 277:7996-8003.
57. Yu C.L., Meyer D.J., Campbell G.S., Larner A.C., Carter-Su C., Schwartz J., et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995, 269:81-83.
58. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.
59. Zemann B., Kinzel B., Muller M., Reuschel R., Mechtcheriakova D., Urtz N., et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006, 107:1454-1458.
60. Zhang H., Desai N.N., Olivera A., Seki T., Brooker G., Spiegel S. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. JCell Biol 1991, 114:155-167.